Circulating Tumor DNA (CtDNA) Methylation Market Future Outlook: Strong Growth Expected Toward $2.74 Billion by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
By how much is the Circulating Tumor DNA (CtDNA) Methylation Market expected to grow between 2026 and 2030?
The circulating tumor DNA (ctDNA) methylation market has experienced rapid expansion in recent years. It is forecast to increase from $1.48 billion in 2025 to $1.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.4%. The historical growth of this market is attributable to advancements in methylation detection, the growth observed in cancer diagnostics, the increasing adoption of liquid biopsy, rising levels of clinical research, and the demand for personalized medicine.
The circulating tumor dna (ctdna) methylation market size is poised for rapid expansion over the next few years. It is projected to climb to $2.74 billion by 2030, achieving a compound annual growth rate (CAGR) of 13.1%. This anticipated growth within the forecast period can be primarily attributed to the advancement of targeted methylation panels, AI-powered methylation analysis, the establishment of early detection programs, increasing oncology research activities, and market penetration into emerging economies. Significant trends anticipated during this period encompass epigenetic biomarker analysis, its integration with liquid biopsy techniques, real-time monitoring of tumor methylation, non-invasive cancer profiling methods, and sophisticated ctdna methylation kits.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28167&type=smp
Which Drivers Are Influencing Market Acceleration In The Circulating Tumor DNA (CtDNA) Methylation Market?
The rising incidence of cancer is expected to boost the expansion of the circulating tumor DNA (ctDNA) methylation market in the coming years. The prevalence of cancer is increasing due to aging populations and lifestyle-related risk factors, including poor dietary habits, smoking, and insufficient physical activity, which heighten the chances of genetic mutations and tumor development. Circulating tumor DNA (ctDNA) methylation assays are beneficial for early, non-invasive cancer detection, enable accurate monitoring of disease progression, and assist in guiding personalized treatment choices, thereby allowing for timely and precise clinical interventions. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, the count of cancer survivors in the United States is forecast to climb from 18.1 million in 2022 to 26 million by 2040. Therefore, the increasing prevalence of cancer is a key factor driving the growth of the ctDNA methylation market.
What Segments Are Identified Within The Structure Of The Circulating Tumor DNA (CtDNA) Methylation Market?
The circulating tumor dna (ctdna) methylation market covered in this report is segmented –
1) By Product Type: Reagents And Kits, Instrumentations, Software And Bioinformatics Solutions, Services
2) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, Other Technologies
3) By Sample Type: Blood Samples, Urine Samples, Saliva Samples, Tissue Samples, Other Sample Types
4) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications
5) By End-User: Hospitals And Clinics, Research Laboratories, Diagnostic Laboratories, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Reagents And Kits: Cell Free DNA Extraction Kits, Bisulfite Conversion Kits, Methylation Detection Kits, Library Preparation Kits, Targeted Enrichment Kits
2) By Instrumentations: Sequencers, Real Time Polymerase Chain Reaction Systems, Digital Polymerase Chain Reaction Systems, Microarray Scanners, Droplet Digital Polymerase Chain Reaction Systems
3) By Software And Bioinformatics Solutions: Data Analysis Software, Methylation Pattern Interpretation Software, Genomic Visualization Tools, Pipeline Automation Software, Clinical Reporting Software
4) By Services: Sample Processing Services, Sequencing Services, Bioinformatics Analysis Services, Clinical Trial Support Services, Consultation And Training Services
What Trends Are Projected To Support The Growth Of The Circulating Tumor DNA (CtDNA) Methylation Market?
Leading companies in the circulating tumor DNA (ctDNA) methylation market are increasingly focused on developing multi-cancer early detection (MCED) blood tests. These tests work by analyzing cancer-specific methylation patterns in ctDNA, thereby facilitating the early and non-invasive identification of numerous cancer types. MCED tests contribute to better patient outcomes by pinpointing unique methylation signatures, which enables timely medical intervention and guides more accurate clinical decisions. For instance, in September 2025, Exact Sciences Corporation, a US-based molecular diagnostics company, introduced Cancerguard, an MCED blood test that integrates ctDNA methylation analysis. Cancerguard is capable of identifying unique methylation signatures across more than 50 cancer types, providing highly sensitive and non-invasive detection, offering actionable insights for clinicians, and supporting continuous monitoring and treatment decisions. This product launch signifies a crucial stride towards early intervention and enhanced survival rates through precision cancer care.
Which Key Market Players Are Investing In Expansion And Innovation Within The Circulating Tumor DNA (CtDNA) Methylation Market?
Major companies operating in the circulating tumor dna (ctdna) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled
Access The Complete Report For Deeper Market Insights:
Which Regions Are Poised For Strategic Growth In The Circulating Tumor DNA (CtDNA) Methylation Market?
North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the circulating tumor dna (ctdna) methylation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Circulating Tumor DNA (CtDNA) Methylation Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28167&type=smp
Browse Through More Reports Similar to the Global Circulating Tumor DNA (CtDNA) Methylation Market 2026, By The Business Research Company
Tumor Infiltrating Lymphocytes Global Market Report 2026
Cell Culture Media Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-culture-media-global-market-report
Cell And Gene Therapy Supply Chain Or Logistics Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.